We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 31.00
Bid: 30.00
Ask: 32.00
Change: 0.50 (1.64%)
Spread: 2.00 (6.667%)
Open: 31.00
High: 31.00
Low: 31.00
Prev. Close: 30.50
IKA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Replacement: Trading update

17 Mar 2017 18:25

RNS Number : 8736Z
Ilika plc
17 March 2017
 

A number of non material typographical changes have been made to the 'Trading update' announcement released on 17 March 2017 at 07.00 under RNS No 7455Z.

 

The changes are identified with an asterisk (*).

 

The full amended text is shown below.

 

17 March 2017

Ilika plc

("Ilika" or the "Company")

 

Trading update

 

Ilika (AIM: IKA), a pioneer in materials innovation and solid-state battery technology, announces the following update on trading.

 

Revenue update

Since its last trading update in November 2016, the Company has announced four significant commercial deals, which are resulting in a strong ramp-up of revenue relative to 2015/16 and which will continue to support revenue growth into 2017/18. We expect to start 2017/18 with a record level of revenue commitments amounting to around £1.8m.

 

Ilika's stated business aim is to add licensing revenue to the development revenue it currently generates. While levels of interest are encouraging, predicting the timing of when these licenses will generate revenue remains a significant forecasting challenge for the Company. Given our proximity to the end of Ilika's current financial year and the duration of negotiations with OEM potential licensees, it seems increasingly likely that revenue from licensing may first have an impact in 2017/18.

 

Stereax roadmap update

Ilika has continued to develop its Stereax intellectual property in accordance with its roadmap, which it updates in line with feedback from its pipeline of development partners. Earlier this month, Ilika confirmed that it had secured a partnership with a bioelectronics company*, focused on optimising the Stereax platform for use in miniature medical implants*. Bioelectronics is a rapidly developing market with large opportunities that match the unique benefits that Stereax offers. Stereax's high volumetric energy density, manufacturability at mm-scale and the ability to deliver pulses of power are ideal for such devices. *

 

Towards the end of last year, Ilika announced the start of a funded collaborative project with Sharp Laboratories of Europe ("Sharp") to create a device consisting of an integrated StereaxTM solid-state battery and a photovoltaic panel, offering an autonomous energy harvesting device for wireless components. The initial concept was designed to address opportunities in automotive and wearables, but publicity around the project has also attracted interest from consumer goods companies looking for innovative ways to promote their products in retail outlets.

 

The next product milestone on Ilika's Stereax roadmap is its industrial battery, code-named Endeavour, which will be able to operate in an extended temperature range covering -40 to 150 degree Celsius. This battery is designed to meet the requirements of Industrial IoT, sometimes called Industry 4.0. A discussion of applications is covered in our recently-posted video featuring Meggitt and IBM which can be found here - http://www.ilika.com/news/videos.

 

Materials development programmes

While the Company is deploying most of its operational and commercial resources on Stereax activities, it has also seen an increase in materials development programmes on its high throughput technology platform. Last month Ilika announced that it had received notification of a renewal of the commercial relationship it has with Seagate to develop photonic materials and processes for Hard Disk Drive ("HDD") technology.

 

Ilika has also recently announced the renewal and strengthening of its long-standing relationship with Toyota. This has been triggered by the award of a contract by the Toyota Research Institute in the USA, which was founded at the end of 2015 with an initial focus on artificial intelligence, robotics and materials innovation.

 

The Company will announce a more detailed update on the outturn for 2016/17 in May prior to issuing its full year results in July.

 

Graeme Purdy, CEO of Ilika, commented: "We are continuing to see a reinforcement of our customer relationships, with long-standing partnerships with companies like Toyota and Seagate being further cemented. It's also great to see the upturn in revenues relative to last year allowing us to start 2017/18 with such a strong order book. The number of potential licensees, their level of interest and the diversity of applications is giving us growing confidence in our licensing model."

 

For more information contact:

 

Ilika plc

www.ilika.com

Graeme Purdy, Chief Executive

Tel: 023 8011 1400

Steve Boydell, Finance Director

 

 

 

Numis Securities Limited

Tel: 020 7260 1000

Oliver Cardigan/ Paul Gillam (Corporate Adviser)

 

James Black/ Michael Burke (Corporate Broking)

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 / ilika@walbrookpr.com

Paul Cornelius

Mob: 07866 384 707

Lianne Cawthorne

Mob: 07584 391 303

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBIGDXCBBBGRR
Date   Source Headline
23rd Aug 20131:25 pmRNSPosting of Annual Report & Notice of AGM
2nd Aug 20135:02 pmRNSConversion of Securities
30th Jul 20137:00 amRNSContract Renewals and Grant Award
19th Jul 20132:50 pmRNSHolding(s) in Company
19th Jul 201311:17 amRNSHolding(s) in Company
18th Jul 20137:00 amRNS£3.3 million EPSRC Grant Award to Southampton Univ
15th Jul 20137:00 amRNSFinal Results
21st May 20131:09 pmRNSHolding(s) in Company
20th May 20137:00 amRNSDirectorate Change and Conversion of Securities
17th May 20133:57 pmRNSPlacing - Replacement
17th May 20137:00 amRNSPlacing
1st May 20137:00 amRNSFuel Cell Catalyst Patent Granted in Japan
22nd Apr 20137:00 amRNSContract with new European Customer
16th Apr 20137:00 amRNSTrading Update
21st Feb 20137:00 amRNSRenewal of Contract
29th Jan 20137:00 amRNSCompletion of Laboratory Facility Expansion
18th Jan 20133:28 pmRNSHolding(s) in Company
17th Jan 20135:46 pmRNSHolding(s) in Company
17th Jan 201311:16 amRNSHolding(s) in Company
15th Jan 20135:21 pmRNSHolding(s) in Company
10th Jan 20137:00 amRNSInterim Results
21st Dec 20127:00 amRNSGrant of Fuel Cell Catalyst Patent
18th Dec 20121:41 pmRNSCompletion of Disposal
17th Dec 20127:00 amRNSConversion of Securities
11th Dec 20127:00 amRNSRenewal of Contract
29th Nov 20124:44 pmRNSHolding(s) in Company
28th Nov 20125:00 pmRNSHolding(s) in Company
27th Nov 20122:18 pmRNSHolding(s) in Company
19th Nov 20127:00 amRNSEnergizer Relationship Update
22nd Oct 20127:00 amRNSTrading Update
5th Oct 20127:00 amRNSHolding(s) in Company
5th Oct 20127:00 amRNSTotal Voting Rights
18th Sep 20127:00 amRNSDiscontinuing of wound care products and services
14th Sep 20127:00 amRNSCarbon Trust Investment
7th Sep 20121:27 pmRNSResult of AGM
7th Sep 20127:00 amRNSAGM Statement
9th Aug 20127:00 amRNSPosting of Annual Report & Notice of AGM
19th Jul 20127:00 amRNSFinal Results
14th Jun 20127:14 amRNSChange of Adviser
1st Jun 201210:01 amRNSTotal Voting Rights
18th May 20127:00 amRNSTrading Update
17th May 20127:00 amRNSConversion of Securities
2nd May 20127:00 amRNSVapour Deposition Method US Patent Grant
1st May 20123:00 pmRNSHolding(s) in Company
30th Apr 201210:27 amRNSDirector's Dealings
30th Apr 201210:22 amRNSTotal Voting Rights
25th Apr 20122:02 pmRNSHolding(s) in Company
23rd Apr 20122:44 pmRNSHolding(s) in Company
23rd Apr 20128:01 amRNSDirector/PDMR Shareholding
20th Apr 201212:49 pmRNSGeneral Meeting Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.